

**Washington State Pharmacy and Therapeutics Committee
Drug Utilization Review Board
Date: June 20, 2018
Time: 9 a.m. to 3:30 p.m.
Port of Seattle “International A” Conference Room
Seattle-Tacoma International Airport
17801 International Blvd., Seattle, WA 98158**

9 a.m.	Welcome & Introductions Pharmacy & Therapeutics Committee Convenes	Lisa Chew, Committee Chair
9:05 a.m.	TIMs report <ul style="list-style-type: none"> Stakeholder input* Motion 	Gerald Gartlehner, OHSU
9:35 a.m.	Overactive Bladder report <ul style="list-style-type: none"> Stakeholder input* Motion 	Ian Blazina, OHSU
10:05 a.m.	Anticoagulant scan <ul style="list-style-type: none"> Stakeholder input* Motion 	Ian Blazina, OHSU
10:15 a.m.	Break	All
10:30 a.m.	ADHD scan <ul style="list-style-type: none"> Stakeholder input* Motion 	Ian Blazina, OHSU
10:40 a.m.	Antidepressants scan Antidepressants- Other, SSRIs <ul style="list-style-type: none"> Stakeholder input* P&T motion DUR motion 	Ian Blazina, OHSU Umang Patel, Magellan
11:10 a.m.	Pharmacy & Therapeutics Committee Adjourns Drug Utilization Review (DUR) Board Convenes	Lisa Chew, Committee Chair
11:10 a.m.	Therapeutic class review: After each drug class presentation will be stakeholder input then a motion made by the DUR Board. <ul style="list-style-type: none"> Alzheimer's agents* Antimigraine agents- Other, Triptans* Immunomodulators, topical* 	Umang Patel, Magellan
12 p.m.	Lunch	All
1 p.m.	Antipsychotic Age Dose Limits <ul style="list-style-type: none"> Stakeholder input* DUR motion 	Dr. Robert Hilt, Seattle Childrens
2 p.m.	Break	All
2:15 p.m.	Therapeutic class review:	Umang Patel, Magellan

** Stakeholders will be allowed 3 minutes for comments. Stakeholder sign in sheets are in the lobby.
Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.

	<p>After each drug class presentation will be stakeholder input then a motion made by the DUR Board.</p> <ul style="list-style-type: none"> • Idiopathic Pulmonary Fibrosis* • Intranasal Rhinitis agents* • Leukotriene modifiers* • NSAIDS* • Proton Pump Inhibitors* <ul style="list-style-type: none"> ○ AH Policy 	<p>April Phillips, HCA will present AH Policy</p>
<p>3:30 p.m.</p>	<p>Drug Utilization Review Board Adjourns</p>	<p>Lisa Chew, Committee Chair</p>

** Stakeholders will be allowed 3 minutes for comments. Stakeholder sign in sheets are in the lobby. Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.